Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Shares Outstanding (Diluted Average) (2016 - 2024)

Historic Shares Outstanding (Diluted Average) for Immucell (ICCC) over the last 15 years, with Q2 2024 value amounting to $7.8 million.

  • Immucell's Shares Outstanding (Diluted Average) rose 81.55% to $7.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.8 million, marking a year-over-year increase of 81.55%. This contributed to the annual value of $7.7 million for FY2023, which is 3.31% up from last year.
  • As of Q2 2024, Immucell's Shares Outstanding (Diluted Average) stood at $7.8 million, which was up 81.55% from $7.7 million recorded in Q4 2023.
  • Over the past 5 years, Immucell's Shares Outstanding (Diluted Average) peaked at $7.8 million during Q3 2021, and registered a low of $7.2 million during Q1 2020.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $7.6 million, with a median of $7.7 million in 2022.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 2728.94% in 2020, then tumbled by 93.9% in 2022.
  • Over the past 5 years, Immucell's Shares Outstanding (Diluted Average) (Quarter) stood at $7.2 million in 2020, then increased by 5.25% to $7.6 million in 2021, then grew by 2.01% to $7.7 million in 2022, then grew by 0.03% to $7.7 million in 2023, then increased by 0.8% to $7.8 million in 2024.
  • Its last three reported values are $7.8 million in Q2 2024, $7.7 million for Q4 2023, and $7.7 million during Q3 2023.